Neoplasms - Immunology
Research News and Information

Monday, November 23, 2009

The shared tumor associated antigen cyclin-A2 is recognized by high-avidity T-cells.

13 Nov 2009 Cyclin-A2, a key cell cycle regulator, has been shown to be overexpressed in various types of malignancies with little expression in normal tissue. Such tumor-associated genes potentially are useful targets for cancer immunotherapy. However, ... Read more...

Cancer risk evaluation in psoriasis: in search of the Holy Grail?

30 Oct 2009 Benefit-risk assessment of systemic treatment in psoriasis is a dynamic process. Long-term safety of psoriasis therapies has been questioned, with the spectrum of systemic immunosuppression potentially leading to increased cancer risk. In this ... Read more...

STATs in cancer inflammation and immunity: a leading role for STAT3.

30 Oct 2009 Commensurate with their roles in regulating cytokine-dependent inflammation and immunity, signal transducer and activator of transcription (STAT) proteins are central in determining whether immune responses in the tumour microenvironment promote or ... Read more...

Latest indexed articles for 'Neoplasms - Immunology'

These are the very latest articles for this heading:

• The shared tumor associated antigen cyclin-A2 is recognized by high-avidity T-cells. 13 Nov 2009
• Cancer risk evaluation in psoriasis: in search of the Holy Grail? 30 Oct 2009
• STATs in cancer inflammation and immunity: a leading role for STAT3. 30 Oct 2009
• In vivo expansion of activated naive CD8+ T cells and NK cells driven by complexes of IL-2 and anti-IL-2 monoclonal antibody as novel approach of cancer immunotherapy. 13 Oct 2009
• Cancer and viral infections in immunocompromised individuals. 13 Oct 2009
• Cancer incidence and risk factors after solid organ transplantation. 13 Oct 2009
• Protumor vs antitumor functions of IL-17. 29 Sep 2009
• Notice of incomplete referencing. 29 Sep 2009
• Adoptively transferred effector cells derived from naive rather than central memory CD8+ T cells mediate superior antitumor immunity. 22 Sep 2009
• Announcing the tumor immunology and biological cancer therapy section (edited by iSBTc) of the Journal of Translational Medicine. 15 Sep 2009
• A shot at cancer. 12 Sep 2009
• Calreticulin maintains the low threshold of peptide required for efficient antigen presentation. 9 Sep 2009
• Tumor immunology: new perspectives. 6 Sep 2009
• Complement regulators and inhibitory proteins. 2 Sep 2009
• Heterogeneity in cancer: cancer stem cells versus clonal evolution. 2 Sep 2009
• Tumor immunosuppressive environment: effects on tumor-specific and nontumor antigen immune responses. 30 Aug 2009
• Harnessing dendritic cells to generate cancer vaccines. 30 Aug 2009
• Identification of immunologic biomarkers associated with clinical response after immune-based therapy for cancer. 30 Aug 2009
• Targets of protective tumor immunity. 30 Aug 2009
• Immunity against cyclin B1 tumor antigen delays development of spontaneous cyclin B1-positive tumors in p53 (-/-) mice. 30 Aug 2009

See a longer list of these articles.

Technical information about 'Neoplasms'

Definition: New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.

Descriptor UI: D009369

Alternative terms: Neoplasms; Neoplasm; Tumors; Tumor; Benign Neoplasms; Neoplasms, Benign; Benign Neoplasm; Neoplasm, Benign; Cancer; Cancers;

Related Mesh Headings: Antibodies, Neoplasm; Antigens, Neoplasm; Antineoplastic Agents; Carcinogens; DNA, Neoplasm; Oncogenic Viruses; Precancerous Conditions; RNA, Neoplasm; Pleural Effusion, Malignant; Genes, Tumor Suppressor; Anticarcinogenic Agents;

Allowable Qualifiers: blood; blood supply; cerebrospinal fluid; chemically induced; classification; complications; congenital; diagnosis; diet therapy; drug therapy; economics; embryology; enzymology; ethnology; etiology; genetics; history; immunology; metabolism; microbiology; mortality; nursing; epidemiology; parasitology; pathology; physiopathology; prevention & control; psychology; radiography; radionuclide imaging; radiotherapy; rehabilitation; secretion; surgery; therapy; ultrastructure; urine; veterinary; ultrasonography; chemistry; virology;

Tree Number: C04;

Online Note: pre-explosion = NEOPLASMS (PX)

History Note: /diagnosis was NEOPLASM DIAGNOSIS 1964-65; /etiology was NEOPLASM ETIOLOGY 1964-65; /immunology was NEOPLASM IMMUNOLOGY 1964-65; /radiotherapy was NEOPLASM RADIOTHERAPY 1964-65; /therapy was NEOPLASM THERAPY 1964-65; NEOPLASM STATISTICS was heading 1964-65; CARCINOGENESIS was heading 1977

Technical Notes: avoid: too general; prefer specifics; policy: Manual section 24; /chem ind permitted but consider also CARCINOGENS; /class: consider also NEOPLASM STAGING (see note there) but "grading" = /pathol; /etiol: consider also ONCOGENIC VIRUSES; /vet: Manual 24.6+ or TN 136; TN 135: MeSH terms for neoplasms classed by tissue; /drug ther: consider also ANTINEOPLASTIC AGENTS & its specifics; /genet: consider also GENES, TUMOR SUPPRESSOR /immunol: consider also TUMOR ESCAPE; consider also ANTIGENS, NEOPLASM & ANTIBODIES, NEOPLASM; /microbiol: consider also ONCOGENIC VIRUSES; /nurs = the patient, ONCOLOGIC NURSING = the oncologic specialty; /prev: consider also ANTICARCINOGENIC AGENTS; /radiother = the patient, RADIATION ONCOLOGY = the specialty; consider also BRACHYTHERAPY; /second = NEOPLASM METASTASIS but do not confuse with NEOPLASMS, SECOND PRIMARY; familial: consider also NEOPLASTIC SYNDROMES, HEREDITARY; metastatic cancer of unknown origin: index under NEOPLASM METASTASIS; Tumor Key: TN Suppl